Gentian Diagnostics ASA (OSL:GENT)

Market Cap	721.77M
Revenue (ttm)	152.07M
Net Income (ttm)	45.29M
Shares Out	15.42M
EPS (ttm)	2.87
PE Ratio	16.31
Forward PE	26.22
Dividend	0.40 (0.85%)
Ex-Dividend Date	n/a

Volume	713
Average Volume	4,315
Open	45.90
Previous Close	45.00
Day's Range	45.00 - 48.40
52-Week Range	34.80 - 61.00
Beta	0.38
RSI	50.41
Earnings Date	Mar 21, 2025

About Gentian Diagnostics ASA

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentia...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 63
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT